A mixture of the antibiotics sulfamethoxazole and trimethoprom
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Cotrimoxazole

Item No. 30781

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
5-[(3,4,5-trimethoxyphenyl)methyl]-2,4-pyrimidinediamine mixture with 4-amino-N-(5-methyl-3-isoxazolyl)-benzenesulfonamide
CAS Number
8064-90-2
Synonyms
  • TMP-SMX
  • Trimethoprim-Sulfamethoxazole
Molecular Formula
C14H18N4O3 • C10H11N3O3S
Formula Weight
543.6
Purity
≥98%
Formulation (Request formulation change)
A solid
Solubility(Learn about Variance in Solubility)
DMF: 10 mg/mlDMSO: 10 mg/mlDMSO:PBS (pH 7.2) (1:4): 0.2 mg/mlEthanol: 0.3 mg/ml
λmax
271 nm
SMILES
COC1=C(OC)C(OC)=CC(CC2=CN=C(N)N=C2N)=C1.NC3=CC=C(S(NC4=NOC(C)=C4)(=O)=O)C=C3
InChi Code
InChI=1S/C14H18N4O3.C10H11N3O3S/c1-19-10-5-8(6-11(20-2)12(10)21-3)4-9-7-17-14(16)18-13(9)15;1-7-6-10(12-16-7)13-17(14,15)9-4-2-8(11)3-5-9/h5-7H,4H2,1-3H3,(H4,15,16,17,18);2-6H,11H2,1H3,(H,12,13)
InChi Key
WZRJTRPJURQBRM-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    250 mg

    $49

    Add

    500 mg

    $93

    Add

    1 g

    $160

    Add

    5 g

    $655

    Add
    Cayman Chemical
    Neutrophil Biology Wall Poster

    Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.

    DOWNLOAD NOW
    Product Description

    Cotrimoxazole is a mixture of the antibiotics sulfamethoxazole (Item No. 23613) and trimethoprim (Item No. 16473).1,2 It is bactericidal against 12 patient-derived community-acquired methicillin-resistant S. aureus (MRSA) strains when used at a concentration of 0.05 mg/L.2 Cotrimoxazole (240 mg/kg) prevents lung and spleen bacterial colonization in a mouse model of inhaled B. mallei infection, but does not eradicate infection when administered post B. mallei exposure in the same model.3 It also resolves cutaneous tail lesions in a mouse model of S. xylosus infection.4 Formulations containing cotrimoxazole have been used in the treatment of MRSA infections and the prevention of glanders disease in human and veterinary medicine, respectively.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Lewis, E.L., Anderson, J.D., and Lacey, R.W. A reappraisal of the antibacterial action of cotrimoxazole in vitro. J. Clin. Pathol. 27(2), 87-91 (1974).

    2. Kaka, A.S., Rueda, A.M., Shelburne, S.A., III, et al. Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 58(3), 680-683 (2006).

    3. Barnes, K.B., Steward, J., Thwaite, J.E., et al. Trimethoprim/sulfamethoxazole (co-trimoxazole) prophylaxis is effective against acute murine inhalational melioidosis and glanders. Int. J. Antimicrob. Agents 41(6), 552-557 (2013).

    4. Thornton, V.B., Davis, J.A., St. Clair, M.B., et al. Inoculation of Staphylococcus xylosus in SJL/J mice to determine pathogenicity. Contemp. Top. Lab. Anim. Sci. 42(4), 49-52 (2003).